AMGN logo Amgen +
Amgen
+

Amgen (AMGN) Business News

Track Amgen in real time with a live news feed covering Amgen stock news, official press releases, company announcements, and an archive of historical Amgen news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

PRNewsWire

4:01 PM | Thursday | May 7, 2026

news photo
Loading...

THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.

Read full article redirect
4:01 PM | Thursday | May 7, 2026

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

PRNewsWire

THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.

Read full article arrow
News Thumbnail
9:00 AM | Monday | May 4, 2026

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR

PRNewsWire

Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.
-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.

Read full article arrow
News Thumbnail
4:01 PM | Thursday | Apr 30, 2026

AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

PRNewsWire

THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026.

Read full article arrow
News Thumbnail
8:30 AM | Monday | Apr 27, 2026

TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026

GlobeNewsWire

Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System

Read full article arrow
News Thumbnail
4:01 PM | Friday | Apr 24, 2026

AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS

PRNewsWire

THOUSAND OAKS, Calif., April 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of the U.S. financial markets.

Read full article arrow
News Thumbnail
4:00 PM | Wednesday | Apr 22, 2026

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

PRNewsWire

Organizational Changes Further Emphasize Integration of Biology and Technology THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M.

Read full article arrow
News Thumbnail
9:00 AM | Monday | Apr 6, 2026

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

PRNewsWire

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction in Proptosis; Greater Than 3 mm THOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED).

Read full article arrow
News Thumbnail
7:30 AM | Wednesday | Apr 1, 2026

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

Business Wire

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab's investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen's IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-stage small cell lung canc.

Read full article arrow
News Thumbnail
4:45 PM | Saturday | Mar 28, 2026

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

PRNewsWire

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse cardiovascular (CV) events (MACE) in high-risk primary prevention patients without known significant atherosclerosis (buildup of plaque in the arteries) and with diabetes.

Read full article arrow
News Thumbnail
4:01 PM | Wednesday | Mar 4, 2026

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

PRNewsWire

THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026.

Read full article arrow
News Thumbnail